Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction

This publication has 29 references indexed in Scilit:

• Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes
  Circulation, 2003
• Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial
  The Lancet, 2002
• COMPARISON OF THE EFFECTS OF ENALAPRIL AND LOSARTAN ON POSTTRANSPLANTATION ERYTHROCYTOSIS IN RENAL TRANSPLANT RECIPIENTS
  Transplantation, 2001
• The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
  Published by Elsevier ,1996
• Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
  Journal of Clinical Investigation, 1996
• Treatment of Postrenal Transplant Erythrocytosis
  Nephron, 1996
• EFFICACY OF CAPTOPRIL ON POSTTRANSPLANT ERYTHROCYTOSIS
  Transplantation, 1994
• Studies of Left Ventricular Dysfunction (SOLVD)—Rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction
  The American Journal of Cardiology, 1990
• Worsening of Anemia Induced by Long-Term Use of Captopril in Hemodialysis Patients
  American Journal of Nephrology, 1984
• ENALAPRIL (MK-421) AND THE WHITE CELL COUNT AND HAEMATOCRIT
  The Lancet, 1982